{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:05:09Z","timestamp":1776762309307,"version":"3.51.2"},"reference-count":9,"publisher":"Scientific Scholar","content-domain":{"domain":["nmji.in"],"crossmark-restriction":true},"short-container-title":["NMJI"],"abstract":"<jats:p>Buprenorphine transdermal patches (TPs) are used for the management of both acute and chronic pain of varied aetiologies. They offer a convenient and sustained method of drug delivery with a good safety profile. Though nausea and\/or vomiting have been reported with buprenorphine TP, intractable vomiting (without spontaneous resolution) has never been reported before. We report a 45-year-old female who presented with acute exacerbation of chronic low back pain with radiculopathy of bilateral lower limbs. We offered her conservative management initially. Buprenorphine TP (10 mcg\/hour) was applied along with the prescription of a few oral medications. However, the subsequent day, she visited our clinic again with complaints of 6\u20137 episodes of vomiting with persistent nausea over the past 24 hours. Buprenorphine TP-induced vomiting was suspected. The patch was removed promptly, and rescue antiemetics were administered. Monitoring of patients on opioids, even with TPs, is warranted.<\/jats:p>","DOI":"10.25259\/nmji_829_2024","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:06:23Z","timestamp":1771848383000},"page":"167-168","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Buprenorphine transdermal patch induced intractable vomiting in a low backache patient. Are unmonitored patches safe?"],"prefix":"10.25259","volume":"39","author":[{"given":"ANKUR","family":"KHANDELWAL","sequence":"first","affiliation":[{"name":"Department of Anaesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences, Guwahati, Silbharal, Changsari, Guwahati, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANIRBAN","family":"BHATTACHARJEE","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences, Guwahati, Silbharal, Changsari, Guwahati, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KASHIF AKHTAR","family":"AHMED","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences, Guwahati, Silbharal, Changsari, Guwahati, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANKITA","family":"MEDHI","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, All India Institute of Medical Sciences, Guwahati, Silbharal, Changsari, Guwahati, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"10.25259\/NMJI_829_2024\/ref-1","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain\u2014 safety aspects","volume":"2","author":"Likar","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.25259\/NMJI_829_2024\/ref-2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2147\/JPR.S153903","article-title":"Buprenorphine and pain treatment in pediatric patients: An update","volume":"11","author":"Vicencio-Rosas","year":"2018","journal-title":"J Pain Res"},{"key":"10.25259\/NMJI_829_2024\/ref-3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jpainsymman.2012.06.014","article-title":"Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels","volume":"46","author":"Kapil","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.25259\/NMJI_829_2024\/ref-4","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.clinthera.2009.08.022","article-title":"Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: A retrospective cohort study","volume":"31","author":"Gallagher","year":"2009","journal-title":"Clin Ther"},{"key":"10.25259\/NMJI_829_2024\/ref-5","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2165\/11208250-000000000-00000","article-title":"Buprenorphine 5, 10 and 20 \u03bcg\/h transdermal patch: A review of its use in the management of chronic non-malignant pain","volume":"71","author":"Plosker","year":"2011","journal-title":"Drugs"},{"key":"10.25259\/NMJI_829_2024\/ref-6","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.2174\/138161212803582540","article-title":"Non-analgesic effects of opioids: Opioid-induced nausea and vomiting-mechanisms and strategies for their limitation","volume":"18","author":"Coluzzi","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.25259\/NMJI_829_2024\/ref-7","first-page":"121","article-title":"Opioid-induced nausea and vomiting","volume":"1","author":"Smith","year":"2012","journal-title":"Ann Palliat Med"},{"key":"10.25259\/NMJI_829_2024\/ref-8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1053\/ajem.2002.32631","article-title":"Gender differences in narcotic-induced emesis in the ED","volume":"20","author":"Zun","year":"2002","journal-title":"Am J Emerg Med"},{"key":"10.25259\/NMJI_829_2024\/ref-9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1185\/03007995.2013.795139","article-title":"Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: A multicenter, randomized, double-blind study in patients with knee osteoarthritis","volume":"29","author":"Pareek","year":"2013","journal-title":"Curr Med Res Opin"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nmji.in\/buprenorphine-transdermal-patch-induced-intractable-vomiting-in-a-low-backache-patient-are-unmonitored-patches-safe\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nmji.in\/buprenorphine-transdermal-patch-induced-intractable-vomiting-in-a-low-backache-patient-are-unmonitored-patches-safe\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:30:39Z","timestamp":1776760239000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/buprenorphine-transdermal-patch-induced-intractable-vomiting-in-a-low-backache-patient-are-unmonitored-patches-safe\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":9,"alternative-id":["10.25259\/NMJI_829_2024"],"URL":"https:\/\/doi.org\/10.25259\/nmji_829_2024","relation":{},"ISSN":["2583-150X","0970-258X"],"issn-type":[{"value":"2583-150X","type":"electronic"},{"value":"0970-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"167"}}